abstract: The possible role of the @entity10 ( @entity10 ) in @entity2 has been considered. Several animal models use knockout (KO) @entity0 that display @entity3 -like behaviors and this study evaluated the role of @entity10 in the regulation of such behaviors. @entity0 lacking the @entity10 (CB(2)KO) were challenged in open field, light-dark box, elevated plus-maze, tail suspension, step down inhibitory avoidance, and pre-pulse inhibition tests (PPI). Furthermore, the effects of treatment with @entity7 and @entity6 were evaluated using the OF and the PPI test. Gene expression of @entity5 D(2)   ( @entity9 ), adrenergic-a(2C)   (a(2C)r), serotonergic @entity4 (2A) and @entity4 (2C) receptors ( @entity4 (2A)r and @entity4 (2C)r) were studied by RT-PCR in brain regions related to @entity3 . Deletion of @entity10 decreased motor activity in the OF test, but enhanced response to acute @entity7 and produced mood-related alterations, PPI deficit, and @entity1 . Chronic treatment with @entity6 tended to impair PPI in @entity8 @entity0 , whereas it 'normalized' the PPI deficit in CB(2)KO @entity0 . CB(2)KO @entity0 presented increased @entity9 and a(2C)r gene expressions in the prefrontal cortex (PFC) and locus coeruleus (LC), decreased @entity4 (2C)r gene expression in the dorsal raphe (DR), and @entity4 (2A)r gene expression in the PFC. Chronic @entity6 treatment in @entity8 @entity0 left a(2C)r gene expression unchanged, decreased @entity9 gene expression (15    g/kg), and decreased @entity4 (2C)r and @entity4 (2A)r in PFC and DR. In CB(2)KO, the gene expression of @entity9 in the PFC, of a(2C)r in the LC, and of @entity4 (2C)r and @entity4 (2A)r in PFC was reduced; @entity4 (2C)r and @entity4 (2A)r gene expressions in DR were increased after treatment with @entity6 . These results suggest that deletion of @entity10 has a relation with @entity3 -like behaviors. Pharmacological manipulation of @entity10 may merit further study as a potential therapeutic target for the treatment of @entity3 .

title: Deletion of @entity10 cannabinoid receptor induces XXXX -related behaviors in @entity0 .

answer: @entity3


abstract: The possible role of the @entity10 ( @entity10 ) in @entity2 has been considered. Several animal models use knockout (KO) @entity0 that display @entity3 -like behaviors and this study evaluated the role of @entity10 in the regulation of such behaviors. @entity0 lacking the @entity10 (CB(2)KO) were challenged in open field, light-dark box, elevated plus-maze, tail suspension, step down inhibitory avoidance, and pre-pulse inhibition tests (PPI). Furthermore, the effects of treatment with @entity7 and @entity6 were evaluated using the OF and the PPI test. Gene expression of @entity5 D(2)   ( @entity9 ), adrenergic-a(2C)   (a(2C)r), serotonergic @entity4 (2A) and @entity4 (2C) receptors ( @entity4 (2A)r and @entity4 (2C)r) were studied by RT-PCR in brain regions related to @entity3 . Deletion of @entity10 decreased motor activity in the OF test, but enhanced response to acute @entity7 and produced mood-related alterations, PPI deficit, and @entity1 . Chronic treatment with @entity6 tended to impair PPI in @entity8 @entity0 , whereas it 'normalized' the PPI deficit in CB(2)KO @entity0 . CB(2)KO @entity0 presented increased @entity9 and a(2C)r gene expressions in the prefrontal cortex (PFC) and locus coeruleus (LC), decreased @entity4 (2C)r gene expression in the dorsal raphe (DR), and @entity4 (2A)r gene expression in the PFC. Chronic @entity6 treatment in @entity8 @entity0 left a(2C)r gene expression unchanged, decreased @entity9 gene expression (15    g/kg), and decreased @entity4 (2C)r and @entity4 (2A)r in PFC and DR. In CB(2)KO, the gene expression of @entity9 in the PFC, of a(2C)r in the LC, and of @entity4 (2C)r and @entity4 (2A)r in PFC was reduced; @entity4 (2C)r and @entity4 (2A)r gene expressions in DR were increased after treatment with @entity6 . These results suggest that deletion of @entity10 has a relation with @entity3 -like behaviors. Pharmacological manipulation of @entity10 may merit further study as a potential therapeutic target for the treatment of @entity3 .

title: Deletion of XXXX cannabinoid receptor induces @entity3 -related behaviors in @entity0 .

answer: @entity10


abstract: The possible role of the @entity10 ( @entity10 ) in @entity2 has been considered. Several animal models use knockout (KO) @entity0 that display @entity3 -like behaviors and this study evaluated the role of @entity10 in the regulation of such behaviors. @entity0 lacking the @entity10 (CB(2)KO) were challenged in open field, light-dark box, elevated plus-maze, tail suspension, step down inhibitory avoidance, and pre-pulse inhibition tests (PPI). Furthermore, the effects of treatment with @entity7 and @entity6 were evaluated using the OF and the PPI test. Gene expression of @entity5 D(2)   ( @entity9 ), adrenergic-a(2C)   (a(2C)r), serotonergic @entity4 (2A) and @entity4 (2C) receptors ( @entity4 (2A)r and @entity4 (2C)r) were studied by RT-PCR in brain regions related to @entity3 . Deletion of @entity10 decreased motor activity in the OF test, but enhanced response to acute @entity7 and produced mood-related alterations, PPI deficit, and @entity1 . Chronic treatment with @entity6 tended to impair PPI in @entity8 @entity0 , whereas it 'normalized' the PPI deficit in CB(2)KO @entity0 . CB(2)KO @entity0 presented increased @entity9 and a(2C)r gene expressions in the prefrontal cortex (PFC) and locus coeruleus (LC), decreased @entity4 (2C)r gene expression in the dorsal raphe (DR), and @entity4 (2A)r gene expression in the PFC. Chronic @entity6 treatment in @entity8 @entity0 left a(2C)r gene expression unchanged, decreased @entity9 gene expression (15    g/kg), and decreased @entity4 (2C)r and @entity4 (2A)r in PFC and DR. In CB(2)KO, the gene expression of @entity9 in the PFC, of a(2C)r in the LC, and of @entity4 (2C)r and @entity4 (2A)r in PFC was reduced; @entity4 (2C)r and @entity4 (2A)r gene expressions in DR were increased after treatment with @entity6 . These results suggest that deletion of @entity10 has a relation with @entity3 -like behaviors. Pharmacological manipulation of @entity10 may merit further study as a potential therapeutic target for the treatment of @entity3 .

title: Deletion of @entity10 cannabinoid receptor induces @entity3 -related behaviors in XXXX .

answer: @entity0


abstract: BACKGROUND AND AIMS: Gastric @entity2 is a serious complication of portal @entity1 . The optimum endoscopic treatment of @entity2 @entity5 is yet to be defined. We evaluated the use of Beriplast, which is a solution of @entity4 and @entity3 , in controlling @entity5 . @entity0 AND METHODS: Fifteen @entity0 presenting with @entity5 were entered into an open trial of endoscopic gastric intravariceal injection treatment with Beriplast (fibrin sealant) and followed for up to 1 month after endoscopic treatment. RESULTS: There was failure to control @entity2 in one @entity0 . Four @entity0 had rebleeding after the index bleed. All four were reinjected with Beriplast, and the @entity2 was controlled in three. All @entity0 were followed for 30 days, and the 30-day mortality following injection treatment was one. Fourteen @entity0 were discharged from the hospital after the first episode of @entity5 . None of the @entity0 had injection-induced complications. CONCLUSIONS: These results show that Beriplast is a safe and simple endoscopic treatment option and is very effective in controlling @entity5 .

title: Use of fibrin glue (beriplast) in the management of @entity2 XXXX .

answer: @entity5


abstract: BACKGROUND AND AIMS: Gastric @entity2 is a serious complication of portal @entity1 . The optimum endoscopic treatment of @entity2 @entity5 is yet to be defined. We evaluated the use of Beriplast, which is a solution of @entity4 and @entity3 , in controlling @entity5 . @entity0 AND METHODS: Fifteen @entity0 presenting with @entity5 were entered into an open trial of endoscopic gastric intravariceal injection treatment with Beriplast (fibrin sealant) and followed for up to 1 month after endoscopic treatment. RESULTS: There was failure to control @entity2 in one @entity0 . Four @entity0 had rebleeding after the index bleed. All four were reinjected with Beriplast, and the @entity2 was controlled in three. All @entity0 were followed for 30 days, and the 30-day mortality following injection treatment was one. Fourteen @entity0 were discharged from the hospital after the first episode of @entity5 . None of the @entity0 had injection-induced complications. CONCLUSIONS: These results show that Beriplast is a safe and simple endoscopic treatment option and is very effective in controlling @entity5 .

title: Use of fibrin glue (beriplast) in the management of XXXX @entity5 .

answer: @entity2


abstract: AIM: This study was designed to retrospectively review our experience with the multimodality management of @entity4 ( @entity4 ). MATERIALS AND METHODS: Thirteen @entity0 were treated for @entity4 between 2000 and 2007. The clinical presentations, chemotherapy tolerance and response, surgical procedure undertaken, and complications were analysed. RESULTS: Median age of the population was 12 months (3-60 months), with a male-to-female ratio of 3.3:1. Nine @entity0 were treated with neoadjuvant chemotherapy incorporating @entity2 and @entity1 . Primary surgery was done in four @entity0 . Extent of hepatic resection in the operated @entity0 varied. Mixed type was the predominant histopathological diagnosis. Adjuvant chemotherapy was well tolerated with no morbidity or mortality. Five-year event-free survival (EFS) and @entity3 ( @entity3 ) of all the 13 @entity0 is 76.9%. All the nine @entity0 who could complete multimodality treatment are alive with no evidence of disease or complications with median follow-up of 63 months (46-122 months). CONCLUSIONS: Treatment of @entity4 with multidisciplinary approach was well tolerated. @entity3 and EFS of @entity0 were comparable with published studies.

title: XXXX : Analysis of treatment outcome from a tertiary care center.

answer: @entity4


abstract: Treatment with opioid medications has grown over the past decades, but has been surrounded by some ongoing controversy and debate to whether it is causing more harm than good for @entity0 . To this end, the field of @entity1 management has suffered from a lack of clarity about some basic definitions on concepts such as tolerance and @entity3 . Some characterize these issues as inevitable parts of opioid therapy while other schools of thought look at these issues as relatively rare occurrences. Unfortunately, most of the rhetoric around these topics has occurred with very little in the realm of real world data. To this end, the authors have reviewed the charts of 197 @entity0 treated by a @entity1 specialist for at least 1 year to better illustrate whether notions of tolerance and @entity3 are common occurrences and, more importantly, whether they occur within any type of specified timeframe. A total of 197 @entity0 charts were reviewed. The sample had an average age of 49.39 years (range = 19-87 years; standard deviation [SD] = 12.48) and comprised 66 @entity0 (33.5 percent) and 131 @entity0 (66.5 percent). The @entity0 were seen in the @entity1 practice for an average of 56.52 months (range = 12-155 months; SD = 31.26). On average, the @entity0 maintained an average daily dose of 180 mg @entity2 equivalents for a period of 35.1 months (range = 3-101 months; SD = 21.3). Looking at the pattern of medication usage change over time, 34.5 percent experienced dose stabilization after the initial titration, 13.2 percent had early dose stabilization within one dose change, and an additional 14.7 percent actually had dose decreases after surgeries or other interventional procedures. Only 6.6 percent of the sample had to be discharged or weaned from controlled substances over time in the clinic. Thus, it appears that tolerance and @entity3 are not foregone conclusions when considering placing a @entity0 on long-term opioid therapy.

title: Defining clinical issues around tolerance, XXXX , and addiction: a quantitative and qualitative outcome study of long-term opioid dosing in a chronic pain practice.

answer: @entity3


abstract: BACKGROUND: Opioid-dependent @entity0 have been shown to have structural brain alterations. This study focuses on magnetic resonance imaging (MRI) measurements of brain and their correlation with the onset age and the duration of @entity6 . METHODS: Brain MRI was obtained from 17 opioid-dependent @entity0 (mean age 34 years, SD 7 years) and 17 controls. Compulsive opioid use had begun between ages 15 and 31 (mean 20) and had continued from 5 to 26 years. All @entity0 were @entity2 smokers, six had also abused @entity4 and 11 @entity5 . Relative volumes of cerebral white matter (WM), gray matter (GM), and cerebrospinal fluid (CSF) spaces were measured. In addition, Sylvian fissure ratio (SFR), bifrontal ratio, and @entity1 were correlated with the onset age and the duration of @entity6 . RESULTS: The total volume (GM + WM + CSF) of the cerebrum was significantly smaller in @entity0 than in controls (Mann-Whitney U-test, p = 0.026) as well as the absolute volumes of GM and WM (p = 0.014 and p = 0.007, respectively). There was no significant difference in GM and WM volumes normalized with total cerebral volume. In contrast, the absolute volume of CSF did not significantly differ between the groups, but the relative volume of CSF was significantly higher in opioid dependents (p = 0.029). SFR and bifrontal ratio were larger in opioid dependents than in controls (p = 0.005 and p = 0.013). The SFR correlated negatively (p = 0.017, r = - 0.569) and the area of vermis cerebelli correlated positively (p = 0.043, r = 0.496) with the onset age of @entity6 . The length of @entity6 and the area of vermis cerebellum had a negative correlation (p = 0.038, r = - 0.523) even though the areas of cerebellar vermis did not significantly differ between opioid dependents and controls. The authors speculate that the onset of @entity3 in adolescence or early adulthood may have in part disturbed the late brain maturation process, as in normal development, the dorsolateral frontal cortex and superior parts of the temporal lobes are the last to maturate. Also, the cerebellar vermis may be affected by early onset @entity3 . It is possible that the brain is more vulnerable to @entity3 at a young age than later in life.

title: Cerebral measurements and their correlation with the onset age and the duration of XXXX .

answer: @entity6


abstract: Notch activation in aortic endothelial cells (ECs) takes place at embryonic stages during cardiac valve formation and induces endothelial-to-mesenchymal transition (EndMT). Using aortic ECs, we show here that active Notch expression promotes EndMT, resulting in downregulation of @entity2 ( @entity2 ) and upregulation of mesenchymal genes such as those for fibronectin and @entity9 . In these cells, @entity1 exacerbates Notch effects by increasing @entity5 and fibronectin activation. When Notch-downstream pathways were analyzed, we detected an increase in @entity6 ( @entity6 ) phosphorylation and inactivation that facilitates @entity5 nuclear retention and protein stabilization. However, the total activity of @entity0 was downregulated. The discrepancy between @entity0 activity and @entity6 phosphorylation is explained by a Notch-induced switch in the @entity0 isoforms, whereby @entity0 , the predominant isoform expressed in ECs, is decreased and @entity8 transcription is upregulated. Mechanistically, @entity8 induction requires the stimulation of the @entity3 / @entity7 transcriptional complex, which activates the @entity8 promoter. Active, phosphorylated @entity8 translocates to the nucleus in Notch-expressing cells, resulting in @entity6 inactivation in this compartment. @entity8 , but not @entity0 , colocalizes in the nucleus with lamin B in the nuclear envelope. In addition to promoting @entity6 inactivation, Notch downregulates @entity4 ( @entity4 ), another @entity8 nuclear substrate. Moreover, Notch protects ECs from oxidative stress-induced apoptosis through an @entity8 - and @entity5 -dependent mechanism.

title: A Switch in @entity0 Isoforms Is Required for Notch-Induced XXXX Expression and Protection from Cell Death.

answer: @entity5


abstract: Notch activation in aortic endothelial cells (ECs) takes place at embryonic stages during cardiac valve formation and induces endothelial-to-mesenchymal transition (EndMT). Using aortic ECs, we show here that active Notch expression promotes EndMT, resulting in downregulation of @entity2 ( @entity2 ) and upregulation of mesenchymal genes such as those for fibronectin and @entity9 . In these cells, @entity1 exacerbates Notch effects by increasing @entity5 and fibronectin activation. When Notch-downstream pathways were analyzed, we detected an increase in @entity6 ( @entity6 ) phosphorylation and inactivation that facilitates @entity5 nuclear retention and protein stabilization. However, the total activity of @entity0 was downregulated. The discrepancy between @entity0 activity and @entity6 phosphorylation is explained by a Notch-induced switch in the @entity0 isoforms, whereby @entity0 , the predominant isoform expressed in ECs, is decreased and @entity8 transcription is upregulated. Mechanistically, @entity8 induction requires the stimulation of the @entity3 / @entity7 transcriptional complex, which activates the @entity8 promoter. Active, phosphorylated @entity8 translocates to the nucleus in Notch-expressing cells, resulting in @entity6 inactivation in this compartment. @entity8 , but not @entity0 , colocalizes in the nucleus with lamin B in the nuclear envelope. In addition to promoting @entity6 inactivation, Notch downregulates @entity4 ( @entity4 ), another @entity8 nuclear substrate. Moreover, Notch protects ECs from oxidative stress-induced apoptosis through an @entity8 - and @entity5 -dependent mechanism.

title: A Switch in XXXX Isoforms Is Required for Notch-Induced @entity5 Expression and Protection from Cell Death.

answer: @entity0


abstract: BACKGROUND: The @entity10 is a mode of administration that provides greater security by allowing more accurate titration of the anesthetic agent. It leads to a better adaptation to the desired effects, and provide a great interest for the realization of anesthetic induction and the prediction of waking for a well- determined population. OBJECTIVE: The aim of our prospective study was to evaluate the feasibility of @entity10 in @entity0 with @entity9 undergoing laparoscopic surgery for @entity1 . METHODS: Thirty @entity0 were included in this study. Age and BMI means were 32 years and 49.31 kg / m2. Our protocol was proposed to associate an hypnotic agent ( @entity7 ) to an opioid one ( @entity8 ) using the technique of the @entity10 , with respectively Schnider and Minto models. RESULTS: The induction protocol has brought good conditions for laryngoscopy with no @entity2 peak or desaturation episode. The period of unconsciousness was 89 seconds with an average target concentration of @entity7 of 5.1 mg / ml. We also noted hemodynamic stability in 79% of @entity0 at induction. During both preparation phase and final installation of the @entity0 , a low ERC to 2 hg / ml was consistent with a suitable hemodynami profile. We obtained hemodynamic stability by adapting target concentration of @entity8 at different operating times ( @entity5 : 3.64 hg / ml, insufflation of the peritoneum: 5.37 hg / ml, jejuno-jejunal resection @entity3 : 9 hg / ml, gastric resection and gastrojejunal @entity3 : 14.2 hg / ml). During this period, no episodes of @entity6 or @entity4 were noticed. During the recovery phase and while doing the distribution of CEP and CER according to the BMI of @entity0 , we identified two groups: Group 1 (BMI <49 kg / m2): fast time extubation (11 min) and target concentrations of @entity7 and @entity8 respectively at 1.3 mg / ml and 1.25 hg / ml which is similar to most publications on this subject and Group 2 (BMI> 49 kg / m2): time-delayed extubation (23 min) with very low values of CEP and CER inconsistent with the literature data.

title: [Target-controlled intravenous anesthesia during laparoscopic surgery for XXXX ].

answer: @entity1


abstract: OBJECTIVES: Behavioral multimodal therapeutic approaches have proven effective in the treatment of @entity4 . Yet there are hardly any findings regarding the effectiveness of outpatient treatment approaches. This article introduces an intensive behavioral therapeutic program for the reduction of @entity2 (VIA - Verhaltenstherapeutisches Intensivprogramm zur Reduktion @entity2 ). VIA combines a intensive outpatient group program for @entity0 , aged 8 to 14 years, with accompanying parent training. This study investigates the effectiveness of the VIA approach in reducing aggressive and comorbid symptoms. Furthermore, it pursues the question of the differential therapy effectiveness. METHODS: We evaluated the treatment program within the framework of a waitlist-group study design. Pre-post changes and predictors of treatment efficacy were assessed via multivariate analyses of variance and a linear regression model, respectively. RESULTS: A group of 36 @entity0 and their caregivers took part in the study. The between-groups comparison revealed a significantly greater reduction of @entity2 and co-morbid symptoms of @entity1 in the intervention group (IG, n = 18) compared to the @entity3 ( @entity3 , n = 18). In addition, age and degree of dissocial-aggressive behavioral symptoms were identified as crucial predictors. CONCLUSIONS: This study shows that the VIA intensive therapeutic treatment program is effective in @entity2 and comorbid @entity1 symptoms in @entity0 with @entity4 .

title: [VIA--an intensive therapeutic treatment program for XXXX ].

answer: @entity4


abstract: PURPOSE: @entity2 of the caudal portion of the subscapularis (SSC) tendon are rare and have not been subject of major attention in the literature yet. However, these lesions can lead to @entity1 of shoulder function. The purpose of the present study was to raise clinician's awareness for these "hidden lesions" and to present the crucial steps for diagnosis and management. METHODS: Five @entity0 (three @entity0 , two @entity0 ; mean age 40) with traumatic isolated caudal SSC lesion were enrolled in the present study. After clinical and radiological examination, all @entity0 underwent diagnostic arthroscopy and open inferior SSC repair. The results of the clinical and radiological examination were documented along with the intraoperative findings. Post-operative @entity3 level and shoulder function were assessed. RESULTS: In all @entity0 the SSC lesion could be detected clinically. In two @entity0 the caudal SSC tear was diagnosed delayed after initial conservative treatment. Preoperatively, all @entity0 showed restricted active movement of the shoulder with positive clinical tests for the SSC. All SSC lesions could be detected on MR images and identified arthroscopically. After a mean follow-up of 12  months, all clinical SSC tests were negative, and the @entity0 have almost regained preinjury shoulder function. The mean post-operative @entity3 score (VAS) was 1 (range 0-1), and the mean ASES score was 93.3 (range 91.6-95). CONCLUSION: Arthroscopic visualization of the SSC tendon is incomplete rendering caudal SSC tears difficult to detect and easy to overlook. Clinicians' awareness of this pathology along with accurate clinical and radiological examination leads to the correct diagnosis. Open caudal SSC repair provides @entity3 relief and reliable shoulder function after short-term follow-up. LEVEL OF EVIDENCE: IV.

title: XXXX of the lower subscapularis tendon: diagnosis and management.

answer: @entity2


abstract: BACKGROUND AND OBJECTIVES: @entity1 ( @entity1 ) is a current promising intervention in @entity2 rehabilitation, but more research is warranted for examining its efficacy and the dose-benefit relation. The authors investigated the effects of higher intensity versus lower intensity @entity1 on movements of forearm pronation-supination and wrist flexion-extension relative to conventional rehabilitation (CR) in @entity0 poststroke for a mean of 21 months. METHODS: In this pilot study, 18 @entity0 with initial mean Fugl-Meyer Assessment (FMA) of 37 to 44 for the upper extremity were randomized to higher intensity @entity1 , lower intensity @entity1 , or CR intervention for 4 weeks. The dose of the higher intensity @entity1 was twice the number of repetitions in the lower intensity @entity1 . Outcome measures at pretreatment and posttreatment were administered to @entity0 to evaluate beneficial and adverse effects of interventions. Primary outcomes were the FMA and Medical Research Council scale. RESULTS: There were significant differences in motor function (P = .04) and daily performance (P = .03) among the 3 groups. The higher intensity @entity1 group showed better improvement in motor function, muscle strength, performance of daily activities, and bimanual ability than the other 2 groups. The intensive @entity1 intervention did not induce higher levels of an oxidative DNA biomarker. CONCLUSIONS: Higher intensity of @entity1 that assists forearm and wrist movements may lead to greater improvement in motor ability and functional performance in @entity2 @entity0 . A sample size of only 20 to 25 in each arm of a larger randomized controlled trial is needed to confirm the findings for similar subjects.

title: Effects of treatment intensity in upper limb robot-assisted therapy for XXXX : a pilot randomized controlled trial.

answer: @entity2


abstract: Local cutaneous heating produces vasodilation that is largely @entity5 (NO) dependent. We showed that @entity7 ( @entity7 ) attenuates this by an @entity7 receptor, type 1 ( @entity9 )-dependent mechanism that is reversible with the antioxidant ascorbate, indicating oxidative stress. Reactive @entity0 species (ROS) produced by @entity7 employ @entity6 and @entity8 oxidase pathways. To determine whether these mechanisms pertain to skin, we measured cutaneous local heating with 10  M @entity7 , using @entity11 to inhibit @entity6 oxidase and @entity1 to inhibit @entity8 oxidase. We also inhibited @entity2 with @entity10 , and @entity3 with ebselen. We heated the skin of the @entity4 in 8 healthy volunteers (24.5-29.9 yr old) to 42  C and measured local blood flow to assess the percentage of maximum cutaneous vascular conductance. We remeasured while perfusing @entity1 , @entity11 , @entity12 , and @entity10 through individual microdialysis catheters. This was then repeated with @entity7 combined with antioxidant drugs. @entity10 and @entity11 alone had no effect on the heat response. @entity1 enhanced the entire response (125% of heat alone), while ebselen suppressed the heat plateau (76% of heat alone). @entity7 alone caused significant attenuation of the entire heat response (52%). When added to @entity7 , @entity1 partially reversed the @entity7 attenuation. Heat with ebselen and @entity7 were similar to heat and @entity7 ; ebselen only partially reversed the @entity7 attenuation. @entity11 and @entity10 each partially reversed the attenuation caused by @entity7 . This suggests that ROS, produced by @entity7 via @entity6 and @entity8 oxidase pathways, modulates the response of skin to the application of heat, and thus contributes to the control of local cutaneous blood flow.

title: Reactive XXXX species (ROS) from @entity6 and @entity8 oxidase modulate the cutaneous local heating response in healthy humans.

answer: @entity0


abstract: Local cutaneous heating produces vasodilation that is largely @entity5 (NO) dependent. We showed that @entity7 ( @entity7 ) attenuates this by an @entity7 receptor, type 1 ( @entity9 )-dependent mechanism that is reversible with the antioxidant ascorbate, indicating oxidative stress. Reactive @entity0 species (ROS) produced by @entity7 employ @entity6 and @entity8 oxidase pathways. To determine whether these mechanisms pertain to skin, we measured cutaneous local heating with 10  M @entity7 , using @entity11 to inhibit @entity6 oxidase and @entity1 to inhibit @entity8 oxidase. We also inhibited @entity2 with @entity10 , and @entity3 with ebselen. We heated the skin of the @entity4 in 8 healthy volunteers (24.5-29.9 yr old) to 42  C and measured local blood flow to assess the percentage of maximum cutaneous vascular conductance. We remeasured while perfusing @entity1 , @entity11 , @entity12 , and @entity10 through individual microdialysis catheters. This was then repeated with @entity7 combined with antioxidant drugs. @entity10 and @entity11 alone had no effect on the heat response. @entity1 enhanced the entire response (125% of heat alone), while ebselen suppressed the heat plateau (76% of heat alone). @entity7 alone caused significant attenuation of the entire heat response (52%). When added to @entity7 , @entity1 partially reversed the @entity7 attenuation. Heat with ebselen and @entity7 were similar to heat and @entity7 ; ebselen only partially reversed the @entity7 attenuation. @entity11 and @entity10 each partially reversed the attenuation caused by @entity7 . This suggests that ROS, produced by @entity7 via @entity6 and @entity8 oxidase pathways, modulates the response of skin to the application of heat, and thus contributes to the control of local cutaneous blood flow.

title: Reactive @entity0 species (ROS) from @entity6 and XXXX oxidase modulate the cutaneous local heating response in healthy humans.

answer: @entity8


abstract: Local cutaneous heating produces vasodilation that is largely @entity5 (NO) dependent. We showed that @entity7 ( @entity7 ) attenuates this by an @entity7 receptor, type 1 ( @entity9 )-dependent mechanism that is reversible with the antioxidant ascorbate, indicating oxidative stress. Reactive @entity0 species (ROS) produced by @entity7 employ @entity6 and @entity8 oxidase pathways. To determine whether these mechanisms pertain to skin, we measured cutaneous local heating with 10  M @entity7 , using @entity11 to inhibit @entity6 oxidase and @entity1 to inhibit @entity8 oxidase. We also inhibited @entity2 with @entity10 , and @entity3 with ebselen. We heated the skin of the @entity4 in 8 healthy volunteers (24.5-29.9 yr old) to 42  C and measured local blood flow to assess the percentage of maximum cutaneous vascular conductance. We remeasured while perfusing @entity1 , @entity11 , @entity12 , and @entity10 through individual microdialysis catheters. This was then repeated with @entity7 combined with antioxidant drugs. @entity10 and @entity11 alone had no effect on the heat response. @entity1 enhanced the entire response (125% of heat alone), while ebselen suppressed the heat plateau (76% of heat alone). @entity7 alone caused significant attenuation of the entire heat response (52%). When added to @entity7 , @entity1 partially reversed the @entity7 attenuation. Heat with ebselen and @entity7 were similar to heat and @entity7 ; ebselen only partially reversed the @entity7 attenuation. @entity11 and @entity10 each partially reversed the attenuation caused by @entity7 . This suggests that ROS, produced by @entity7 via @entity6 and @entity8 oxidase pathways, modulates the response of skin to the application of heat, and thus contributes to the control of local cutaneous blood flow.

title: Reactive @entity0 species (ROS) from XXXX and @entity8 oxidase modulate the cutaneous local heating response in healthy humans.

answer: @entity6


abstract: We have retrospectively investigated clinical profile, efficacy, and safety in 41 @entity0 who were treated with liposomal @entity11 ( @entity13 ) in Aichi Medical University Hospital between January 2008 and June 2009. It turned out that @entity13 was used for severe @entity1 and 31.7% cases discontinued @entity13 therapy because of @entity2 . @entity13 was administered as the second-line therapy in 56.1% (23/41), and was not effective in 48.8% (20/41). @entity13 was administered as the first-line therapy in 43.9% (18/41); (1) 1 for @entity3 , (2) 7 for severe @entity4 or @entity5 , (3) 2 for the case which cannot remove medical device and might have biofilm formation, (4) 6 for the induction of step-down therapy concept, (5) 2 for febrile @entity8 @entity0 who have needed aggressive empiric therapy. There was no significant difference in serum @entity6 level (p = 0.10) and serum @entity7 level (p = 0.05) between pretreatment and posttreatment with @entity13 . The serum @entity7 level before initial treatment with @entity13 was 1.31 +/- 1.30 mg/dL. The @entity0 for 7.3% (3 cases) had dialyzed before initial treatment with @entity13 , however, there was no case who need dialysis after administration of @entity13 . As for the highest @entity7 level in @entity13 administered cases, 29.3% (12/41) and 24.4% (10/41) were normal to abnormal, and abnormal to abnormal, respectively. This is the first investigational report when the serum @entity7 level before initial administration of @entity12 had been abnormal. The other antimicrobial agents, which might have influenced renal function, were administered to 51.2% cases (21/41). That means the cases administered @entity13 might have other @entity10 . As for the serum @entity7 level, we observed the changing cases and the cases which did not cause the change at all regardless of the administering period of @entity12 . The serum @entity6 level before initial administration of @entity13 was 4.1 +/- 0.8 mEq/L, concomitant use of @entity9 etc. was 31.7% (13/41), the lowest serum @entity6 level was 3.4 +/- 0.9 (1.9-6.2)mEq/L in during using @entity13 , the serum @entity6 was 34.1% (14/41) in replenish @entity6 during administration of @entity13 , and the total replenished @entity6 was 131.25 mEq. We did not observe the case who had died because of the low @entity6 . Since @entity13 was the only fungicidal drug, when we use @entity13 for the serious @entity1 to make the best use of the characteristic, we have to pay attention to the concomitant medication, renal function and the serum @entity6 level.

title: [Retrospective investigation on the cases treated with liposomal XXXX ].

answer: @entity11


abstract: BACKGROUND: Although atrial high rate episodes (AHRE) have been commonly used to detect @entity3 ( @entity2 /AF) in pacemaker @entity0 , its reliability and characteristics are unclear. METHODS AND RESULTS: 39 @entity0 with implanted dual chamber pacemakers (mean age 79.7    6.6 years), who had no history of @entity2 /AF and were programmed in the setting of AHRE at > 190 beats/min in DDD mode, were studied. An @entity1 ( @entity1 ) algorithm was randomly programmed "ON" in 19 and "OFF" in 20 @entity0 . AHRE were detected in 20 @entity0 (51%), consisting of @entity2 /AF in 15 and repetitive non-reentrant ventriculoatrial synchrony (RNRVAS) in 8 @entity0 , all included in the @entity1 "ON" group. A total of 257 of 1,528 episodes of AHRE were available for analysis, including 181 and 76 episodes in the @entity1 "ON" and "OFF" groups, respectively. Among 181 episodes in the @entity1 "ON" group, 72 (40%) were RNRVAS, whereas all episodes in the @entity1 "OFF" group (100%) were @entity2 /AF. Detection of RNRVAS was closely associated with a high cumulative % atrial pacing. The specificity of @entity2 /AF detection by AHRE was 40% when the @entity1 algorithm was activated, vs. 100% when not in use. CONCLUSIONS: @entity2 /AF was common in pacemaker @entity0 without a history of @entity2 /AF. The increase in cumulative % atrial pacing and the use of an @entity1 algorithm might be closely associated with RNRVAS, non- @entity2 /AF, detected by AHRE.

title: Reliability and characteristics of XXXX in dual chamber pacemakers.

answer: @entity3


abstract: OBJECTIVE: The mature results of the neoadjuvant and adjuvant chemotherapy arms of the nonrandomized, phase 2 Yale University @entity4 , @entity7 , @entity6 , and @entity5 protocol are presented. METHODS: Sixty-seven @entity0 were prospectively accrued with a median follow-up of 5.4 years, and standard parameters of @entity2 and efficacy were studied. Both univariate and multivariate analyses were applied. RESULTS: The 5-year disease-free survival of 78% for the 25 @entity0 in the adjuvant group, of which 80% had high-risk features including positive margins, parametria, and lymph nodes and 28% had @entity3 , was comparable to recent relevant literature. Only 64% of @entity0 in this group received consolidation radiation therapy, which did not impact on survival. Only 12% of @entity0 recurred distantly. Notably, those who received 4 months or more of chemotherapy had prolonged survival (P = 0.012). In the neoadjuvant group, chemotherapy response rate among 42 @entity0 (with stages 1B-IIIB @entity1 ) was 79% (50% partial response, 29% complete response), and no @entity0 progressed. In the subgroup of 22 @entity0 who underwent surgery after chemotherapy, 59% had nonsquamous histology. Forty-five percent of @entity0 with stage IIB @entity1 were deemed operable after chemotherapy. Ninety-five percent received postoperative radiation therapy. There was a 9% pathologic complete response rate, with positive lymph nodes found in 27%. Notably, those who received 3 months or less of chemotherapy had improved overall survival (P = 0.030). Survival rates of these 22 @entity0 at 3 and 5 years were 73% and 63%, respectively. Although not randomized, these survival rates were similar to those achieved with chemoradiation. CONCLUSIONS: Although there are several logistical/design features of the @entity4 , @entity7 , @entity6 , and @entity5 regimen that are not in line with the current chemotherapy era, our experience with this well-tolerated regimen can serve as a proof of principle. Our data suggests that both neoadjuvant and adjuvant @entity4 -based neoadjuvant chemotherapy may have their place. It also raises the possibility that the optimal duration of chemotherapy in adjuvant cases should be longer than in neoadjuvant cases.

title: Neoadjuvant and adjuvant chemotherapy of cervical XXXX : mature results of the phase 2 PBM-PFU protocol.

answer: @entity1


abstract: OBJECTIVE: To assess how enhanced postdischarge telephone follow-up calls would improve case finding for @entity1 ( @entity1 ) surveillance after cesarean section. METHODS: We conducted a prospective cohort study of all @entity0 who delivered by cesarean section between April 22 and August 22, 2010. In addition to our routine surveillance, using clinical databases and electronic @entity0 records, we also made follow-up calls to the @entity0 at 7, 14, and 30 days postoperation. A standard questionnaire with questions about symptoms of @entity1 , health-seeking behaviors, and treatment received was administered. Descriptive statistics and univariate analysis were performed to assess the effect of the enhanced surveillance. RESULTS: One hundred ninety-three @entity0 underwent cesarean section during this study period. Standard surveillance identified 14 infections with telephone follow-ups identifying an additional 5 infections. Using the call as a gold standard, the sensitivity of the standard methodology to capture @entity1 was 73.3%. The duration of the calls ranged from 1 to 5 minutes and were well received by the @entity0 . CONCLUSIONS: Results suggest that follow-up telephone calls to @entity0 following cesarean section identifies 26.3% of the total SSIs. Enhanced surveillance can provide more informed data to enhance performance and avoid underestimation of rates.

title: Postdischarge surveillance for XXXX following cesarean section: A prospective cohort study comparing methodologies.

answer: @entity1


abstract: UNASSIGNED: The vagus nerve is dominated by afferent fibers that convey sensory information from the viscera to the brain. Most vagal afferents are unmyelinated, slow-conducting C-fibers, while a smaller portion are myelinated, fast-conducting A-fibers. Vagal afferents terminate in the nucleus tractus solitarius (NTS) in the dorsal brainstem and regulate autonomic and respiratory reflexes, as well as ascending pathways throughout the brain. Vagal afferents form glutamatergic excitatory synapses with postsynaptic NTS neurons that are modulated by a variety of channels. The organization of vagal afferents with regard to fiber type and channels is not well understood. In the present study, we used tract tracing methods to identify distinct populations of vagal afferents to determine if key channels are selectively localized to specific groups of afferent fibers. Vagal afferents were labeled with isolectin B4 (IB4) or cholera toxin B ( @entity3 ) to detect unmyelinated and myelinated afferents, respectively. We find that @entity1 channels are preferentially found in unmyelinated vagal afferents identified with IB4, with almost half of all IB4 fibers showing co-localization with @entity1 . These results agree with prior electrophysiological findings. In contrast, we found that the @entity0 -sensitive channel @entity2 is found in a subset of both myelinated and unmyelinated vagal afferent fibers. Specifically, 18% of IB4 and 23% of @entity3 afferents contained @entity2 . The majority of @entity3 -ir vagal afferents contained neither channel. Since neither channel was found in all vagal afferents, there are likely further degrees of heterogeneity in the modulation of vagal afferent sensory input to the NTS beyond fiber type.

title: Localization of XXXX and @entity2 in unmyelinated and myelinated vagal afferents in the rat.

answer: @entity1


abstract: UNASSIGNED: The vagus nerve is dominated by afferent fibers that convey sensory information from the viscera to the brain. Most vagal afferents are unmyelinated, slow-conducting C-fibers, while a smaller portion are myelinated, fast-conducting A-fibers. Vagal afferents terminate in the nucleus tractus solitarius (NTS) in the dorsal brainstem and regulate autonomic and respiratory reflexes, as well as ascending pathways throughout the brain. Vagal afferents form glutamatergic excitatory synapses with postsynaptic NTS neurons that are modulated by a variety of channels. The organization of vagal afferents with regard to fiber type and channels is not well understood. In the present study, we used tract tracing methods to identify distinct populations of vagal afferents to determine if key channels are selectively localized to specific groups of afferent fibers. Vagal afferents were labeled with isolectin B4 (IB4) or cholera toxin B ( @entity3 ) to detect unmyelinated and myelinated afferents, respectively. We find that @entity1 channels are preferentially found in unmyelinated vagal afferents identified with IB4, with almost half of all IB4 fibers showing co-localization with @entity1 . These results agree with prior electrophysiological findings. In contrast, we found that the @entity0 -sensitive channel @entity2 is found in a subset of both myelinated and unmyelinated vagal afferent fibers. Specifically, 18% of IB4 and 23% of @entity3 afferents contained @entity2 . The majority of @entity3 -ir vagal afferents contained neither channel. Since neither channel was found in all vagal afferents, there are likely further degrees of heterogeneity in the modulation of vagal afferent sensory input to the NTS beyond fiber type.

title: Localization of @entity1 and XXXX in unmyelinated and myelinated vagal afferents in the rat.

answer: @entity2


abstract: UNASSIGNED: Virulence of Shigella is attributed to the genes presence in chromosome or in the megaplasmid. The apy gene which is located in the megaplasmid of Shigella species encodes for apyrase enzyme, a pathogenesis-associated enzyme causing @entity3 and host cell death. In this study we constructed an apy mutant of @entity7 by insertional activation using a @entity5 resistant gene cassette. The wild type apy gene of @entity8 was PCR amplified, cloned and mutated with insertion of @entity5 resistant gene cassette (aphA). The mutated construct (apy: aphA) was subcloned into a conjugative suicidal vector (pWM91) at the unique Sma1 and Sac1 sites. The mutation of the wild apy gene in the construct was confirmed by DNA sequencing. The mutated construct was introduced into wild type @entity8 by conjugation with @entity0 . After undergoing homologous recombination, the wild apy gene was deleted from the construct using the @entity2 selection method. Non-functional activity of the apyrase enzyme in the constructed strain by colorimetric test indicated the successful mutation of the apyrase enzyme. This strain with mutated apy gene was evaluated for its protective efficacy using the @entity1 @entity6 model. The strain was Sereny negative and it elicited a significant protection following challenge with wild @entity7 . This apy mutant strain will form a base for the development of a vaccine target for @entity4 .

title: Alteration in apyrase enzyme attenuated virulence of XXXX .

answer: @entity7


abstract: BACKGROUND: In the past, @entity2 was histologically classified according to the 1995 WHO Classification. With the introduction of the 2003 ISN/RPS Classification, many nephropathology services converted to this new classification. This study was undertaken to compare both classification systems in a single centre practice. METHODS: 103 consecutive adequate renal biopsies initially reported as @entity2 in the Department of Pathology, Faculty of Medicine, University of Malaya were reassessed using the criteria of both the 1995 WHO Classification and the 2003 ISN/ RPS Classification. RESULTS: The relative prevalence for each class using the WHO Classification were: Class I (1%), Class II (8.7%), Class III (6.8%), Class IV (60.2%), Class V (20.4%), Class VI (2.9%) while the prevalence using the 2003 ISN/RPS Classification were: Class I (1%), Class II (8.7%), Class III (6.8%), Class IV (61.2%), Class V (21.3%), Class VI (1%). Both classifications were essentially comparable with regards to Classes I, II and III. The differences in Classes IV, V and VI were significant in potential to alter @entity0 management. The identification of segmental lesions (Class IV-S) over and above a global @entity1 (Class IV-G) deserves more focused clinicopathological studies to gauge whether these groups have different clinical manifestations and outcomes. With regards Class V, the ISN/RPS system, by requiring that all mixed classes be stipulated in the diagnostic line, minimizes the chances of @entity0 missing out on additional treatment. The ISN/ RPS system has stricter criteria for Class VI, which again minimizes @entity0 missing out on therapy. On the whole, the ISN/RPS system is more user-friendly as criteria are more clearly defined which translates to more benefits to @entity0 care.

title: A comparison of 1995 WHO classification with 2003 ISN/RPS classification of XXXX : a single centre observation.

answer: @entity2


abstract: Nosocomial blood stream infections continue to be a cause of high mortality and morbidity in newborn intensive care units (NICUs). Identification of the causative microorganisms and their antimicrobial sensitivities will guide the selection of appropriate empirical treatment. We prospectively evaluated culture-proven @entity3 cases and antibiotic sensitivity patterns seen in the NICU of Dr. Sami Ulus @entity0 's Hospital, in Ankara, @entity2 during a six-year period (2000-2006). A total of 106 @entity3 attacks were found in 100 @entity0 , with 72 of them preterm. Gram-negative bacteria were isolated at a rate of 70.8%, gram-positive at 22.6% and Candida species (spp.) at 6.6%. The most commonly isolated microorganisms were, in order of frequency, @entity10 spp. (39.6%), @entity4 (11.3%) and Coagulase-negative staphylococci (9.4%). During the study, 12 of the 28 term babies (42.9%) and 26 of the 72 preterm babies (36.1%) died due to @entity3 , with a mortality rate of 38%. Resistance to @entity6 was 100%, to @entity9 88%, to @entity5 73%, and to @entity11 23% in gram-negative bacteria. No @entity7 resistance was found except for @entity4 (25%). Resistance to @entity1 was 100% and @entity8 58.3% in gram-positive bacteria. No glycopeptide or @entity7 resistance was found. In conclusion, @entity3 still has a high mortality rate. Gram-negative bacteria were the most commonly isolated microorganisms with @entity10 spp. being dominant. All gram-negative species were resistant to @entity6 , and all gram-positive bacteria were resistant to @entity1 . No glycopeptide or @entity7 resistance was found in gram-positive bacteria. In gram-negative bacteria, low @entity11 and high @entity5 and @entity12 resistances were found. No @entity7 resistance was found except for @entity4 . Restricted and alternate antibiotic usage policies seem important for the resistance problem.

title: Nosocomial blood stream infections in a neonatal intensive care unit in Ankara, XXXX .

answer: @entity2


abstract: AIM: It is well reported in the scientific literature that there is a high level of periodontal disease and lower caries prevalence in @entity1 ( @entity1 ) individuals, when compared with age-matched non @entity1 individuals. This study was conducted to investigate the process of @entity2 in @entity1 @entity0 . MATERIALS AND METHODS: In this study the following parameters were considered: oral hygiene habits, levels of @entity3 (SM) and Lactobacillus spp. (LB), Modified Gingival Index (MGI), and Simplified Oral Hygiene Index (OHI-S). A case group with @entity1 @entity0 (n=69) and a control group of non @entity1 @entity0 (n=69) were formed to perform this study. @entity2 severity was determined using the DMFT index. Samples of non-stimulated saliva were collected to determine the Lactobacillus spp levels. For SM levels, MSB agar plates were used. RESULTS: The findings revealed that the case group attended dental check-ups more frequently, brushed their teeth more times per day, flossed less, and also more frequently had SM levels classified as high count. The MGI was higher and the OHI-S was lower than the control group (p<0.001). CONCLUSION: No significant differences were found between the DMFT indexes of @entity0 from the two groups (p=0.345). The logistic regression analysis showed that in the case group, age, MGI, and SM count were positively related to @entity2 (p<0.05).

title: Some factors associated with XXXX in the primary dentition of @entity0 with Down syndrome.

answer: @entity2


abstract: AIM: It is well reported in the scientific literature that there is a high level of periodontal disease and lower caries prevalence in @entity1 ( @entity1 ) individuals, when compared with age-matched non @entity1 individuals. This study was conducted to investigate the process of @entity2 in @entity1 @entity0 . MATERIALS AND METHODS: In this study the following parameters were considered: oral hygiene habits, levels of @entity3 (SM) and Lactobacillus spp. (LB), Modified Gingival Index (MGI), and Simplified Oral Hygiene Index (OHI-S). A case group with @entity1 @entity0 (n=69) and a control group of non @entity1 @entity0 (n=69) were formed to perform this study. @entity2 severity was determined using the DMFT index. Samples of non-stimulated saliva were collected to determine the Lactobacillus spp levels. For SM levels, MSB agar plates were used. RESULTS: The findings revealed that the case group attended dental check-ups more frequently, brushed their teeth more times per day, flossed less, and also more frequently had SM levels classified as high count. The MGI was higher and the OHI-S was lower than the control group (p<0.001). CONCLUSION: No significant differences were found between the DMFT indexes of @entity0 from the two groups (p=0.345). The logistic regression analysis showed that in the case group, age, MGI, and SM count were positively related to @entity2 (p<0.05).

title: Some factors associated with @entity2 in the primary dentition of XXXX with Down syndrome.

answer: @entity0


abstract: Evaluation of: Brody JD, Ai WZ, Czerwinski DK et al. In situ vaccination with a @entity4 agonist induces systemic @entity2 regression: a Phase I/II study. J. Clin. Oncol. 28(28), 4324-4332 (2010). Despite high response rates of the follicular B-cell @entity2 to monoclonal antibodies, the clinical course of @entity2 is still characterized by a continuous pattern of relapse. Brody and colleagues treated 15 @entity0 with relapsed, @entity3 using low-dose radiotherapy applied to one of the @entity1 sites with combined injection of a @entity4 agonist at the same site. This strategy induced specific immunity and @entity1 regression in several @entity0 with an objective response rate of 27%. The results indicate an involvement of the @entity1 @entity4 -expressing B cells acting as antigen-presenting cells. @entity4 in situ vaccination combined with local radiotherapy clearly warrants further in-depth analysis and investigation in a Phase III randomized trial, and may provide a new opportunity for the treatment of B-cell @entity1 .

title: Targeting malignant B cells as antigen-presenting cells: @entity4 agonist induces systemic regression of XXXX .

answer: @entity2


abstract: Evaluation of: Brody JD, Ai WZ, Czerwinski DK et al. In situ vaccination with a @entity4 agonist induces systemic @entity2 regression: a Phase I/II study. J. Clin. Oncol. 28(28), 4324-4332 (2010). Despite high response rates of the follicular B-cell @entity2 to monoclonal antibodies, the clinical course of @entity2 is still characterized by a continuous pattern of relapse. Brody and colleagues treated 15 @entity0 with relapsed, @entity3 using low-dose radiotherapy applied to one of the @entity1 sites with combined injection of a @entity4 agonist at the same site. This strategy induced specific immunity and @entity1 regression in several @entity0 with an objective response rate of 27%. The results indicate an involvement of the @entity1 @entity4 -expressing B cells acting as antigen-presenting cells. @entity4 in situ vaccination combined with local radiotherapy clearly warrants further in-depth analysis and investigation in a Phase III randomized trial, and may provide a new opportunity for the treatment of B-cell @entity1 .

title: Targeting malignant B cells as antigen-presenting cells: XXXX agonist induces systemic regression of @entity2 .

answer: @entity4


abstract: BACKGROUND AND PURPOSE: Dysplasia of the hip increases the risk of secondary degenerative change and subsequent total hip replacement. Here we report on age at diagnosis of @entity2 , previous treatment, and quality of life for @entity0 born after 1967 and registered with a total hip replacement due to @entity2 in the Norwegian Arthroplasty Register. We also used the medical records to validate the diagnosis reported by the orthopedic surgeon to the register. METHODS: Subjects born after January 1, 1967 and registered with a primary total hip replacement in the Norwegian Arthroplasty Register during the period 1987-2007 (n = 713) were included in the study. Data on hip symptoms and quality of life (EQ-5D) were collected through questionnaires. Elaborating information was retrieved from the medical records. RESULTS: 540 of 713 @entity0 (76%) (corresponding to 634 hips) returned the questionnaires and consented for additional information to be retrieved from their medical records. @entity1 accounted for 163 of 634 hip replacements (26%), 134 of which were in females (82%). Median age at time of diagnosis was 7.8 (0-39) years: 4.4 years for females and 22 years for males. After reviewing accessible medical records, the diagnosis of @entity1 was confirmed in 132 of 150 hips (88%). INTERPRETATION: One quarter of hip replacements performed in @entity0 aged 40 or younger were due to an underlying @entity1 , which, in most cases, was diagnosed during late childhood. The @entity2 diagnosis reported to the register was correct for 88% of the hips.

title: Total hip replacement in young adults with XXXX : age at diagnosis, previous treatment, quality of life, and validation of diagnoses reported to the Norwegian Arthroplasty Register between 1987 and 2007.

answer: @entity1


abstract: OBJECTIVE: The purpose of this study is to compare early and long-term results in terms of survival and @entity1 of @entity0 with acute traumatic @entity2 who were conservatively managed with @entity0 who underwent surgical or endovascular repair. METHODS: From January 1980 to December 2009, 66 @entity0 with acute traumatic @entity2 were divided into 3 groups according to treatment intention at admission: 37 @entity0 in a conservative group, 22 @entity0 in a surgical group, and 7 @entity0 in an endovascular group. Groups were similar with regard to gender, age, Injury Severity Score, Revised @entity2 Score, and @entity2 Severity Score. RESULTS: In-hospital mortality was 21.6% in the conservative group, 22.7% in the surgical group, and 14.3% in the endovascular group (P = .57). In-hospital @entity3 occurred only in the conservative group. Median follow-up time was 75 months (range, 5-327 months). Conservative group survival was 75.6% at 1 year, 72.3% at 5 years, and 66.7% at 10 years. Surgical group survival remained at 77.2% at 1, 5, and 10 years, whereas survival in the endovascular group was 85.7% at 1 and 5 years (P = .18). No @entity0 in the surgical or endovascular group required reintervention because of @entity3 , whereas 37.9% of the conservative group had an aortic-related complication that required surgery or caused the @entity0 's death during the follow-up period. Cumulative survival free from @entity3 in the conservative group was 93% at 1 year, 88.5% at 5 years, and 51.2% at 10 years. Cox regression confirmed the initial type of aortic lesion (hazard ratio, 2.94; P = .002) and a @entity2 Score-Injury Severity Score greater than 50% on admission (hazard ratio, 1.49; P = .042) as risk factors for the appearance of @entity3 . Two peaks in the complication rate of the conservative group were detected in the first week and between the first and third months after blunt @entity2 . CONCLUSIONS: The advent of thoracic aortic endografting has enabled a revolution in the management of acute traumatic @entity2 in @entity0 with multisystem @entity2 with a low in-hospital morbimortality. Nonoperative management may be only a therapeutic option with acceptable survival in carefully selected @entity0 . The natural history of these @entity0 has revealed a marked trend of late @entity3 developing, which may justify an endovascular repair even in some low-risk @entity0 .

title: Role of conservative management in traumatic XXXX : comparison of long-term results of conservative, surgical, and endovascular treatment.

answer: @entity2


abstract: OBJECTIVES: To test the hypothesis that early @entity4 deprivation therapy (ADT) has no proven survival advantage in older @entity0 with biochemical recurrence (BCR) of @entity3 ( @entity3 ), and it may contribute to geriatric frailty. METHODS: We conducted a case-control study of @entity0 aged 60+ years with BCR on ADT (n = 63) vs @entity3 survivors without recurrence (n = 71). Frailty prevalence, " @entity1 " frailty, Short Physical Performance Battery (SPPB) scores, and falls were compared. An exploratory analysis of frailty biomarkers ( @entity5 , erythrocyte sedimentation rate, hemoglobin, albumin, and total @entity2 ) was performed. Summary statistics and univariate and multivariate regression analyses were conducted. RESULTS: More @entity0 on ADT were @entity1 (body mass index >30; 46.2% vs 20.6%; P = .03). There were no statistical differences in SPPB (P = .41) or frailty (P = .20). Using a proposed " @entity1 " frailty criteria, 8.7% in ADT group were frail and 56.5% were "prefrail," compared with 2.9% and 48.8% of controls (P = .02). Falls in the last year were higher in the ADT group (14.3% vs 2.8%; P = .02). In analyses controlling for age, clinical characteristics, and comorbidities, the ADT group trended toward significance for " @entity1 " frailty (P = .14) and falls (OR = 4.74, P = .11). Comorbidity significantly increased the likelihood of " @entity1 " frailty (P = .01) and falls (OR 2.02, P = .01). CONCLUSIONS: @entity0 with BCR on ADT are frailer using proposed modified " @entity1 " frailty criteria. They may have lower performance status and more falls. A larger, prospective trial is necessary to establish a causal link between ADT use and progression of frailty and disability.

title: Obese frailty, physical performance deficits, and falls in older @entity0 with biochemical recurrence of XXXX on @entity4 deprivation therapy: a case-control study.

answer: @entity3


abstract: OBJECTIVES: To test the hypothesis that early @entity4 deprivation therapy (ADT) has no proven survival advantage in older @entity0 with biochemical recurrence (BCR) of @entity3 ( @entity3 ), and it may contribute to geriatric frailty. METHODS: We conducted a case-control study of @entity0 aged 60+ years with BCR on ADT (n = 63) vs @entity3 survivors without recurrence (n = 71). Frailty prevalence, " @entity1 " frailty, Short Physical Performance Battery (SPPB) scores, and falls were compared. An exploratory analysis of frailty biomarkers ( @entity5 , erythrocyte sedimentation rate, hemoglobin, albumin, and total @entity2 ) was performed. Summary statistics and univariate and multivariate regression analyses were conducted. RESULTS: More @entity0 on ADT were @entity1 (body mass index >30; 46.2% vs 20.6%; P = .03). There were no statistical differences in SPPB (P = .41) or frailty (P = .20). Using a proposed " @entity1 " frailty criteria, 8.7% in ADT group were frail and 56.5% were "prefrail," compared with 2.9% and 48.8% of controls (P = .02). Falls in the last year were higher in the ADT group (14.3% vs 2.8%; P = .02). In analyses controlling for age, clinical characteristics, and comorbidities, the ADT group trended toward significance for " @entity1 " frailty (P = .14) and falls (OR = 4.74, P = .11). Comorbidity significantly increased the likelihood of " @entity1 " frailty (P = .01) and falls (OR 2.02, P = .01). CONCLUSIONS: @entity0 with BCR on ADT are frailer using proposed modified " @entity1 " frailty criteria. They may have lower performance status and more falls. A larger, prospective trial is necessary to establish a causal link between ADT use and progression of frailty and disability.

title: Obese frailty, physical performance deficits, and falls in older @entity0 with biochemical recurrence of @entity3 on XXXX deprivation therapy: a case-control study.

answer: @entity4


abstract: OBJECTIVES: To test the hypothesis that early @entity4 deprivation therapy (ADT) has no proven survival advantage in older @entity0 with biochemical recurrence (BCR) of @entity3 ( @entity3 ), and it may contribute to geriatric frailty. METHODS: We conducted a case-control study of @entity0 aged 60+ years with BCR on ADT (n = 63) vs @entity3 survivors without recurrence (n = 71). Frailty prevalence, " @entity1 " frailty, Short Physical Performance Battery (SPPB) scores, and falls were compared. An exploratory analysis of frailty biomarkers ( @entity5 , erythrocyte sedimentation rate, hemoglobin, albumin, and total @entity2 ) was performed. Summary statistics and univariate and multivariate regression analyses were conducted. RESULTS: More @entity0 on ADT were @entity1 (body mass index >30; 46.2% vs 20.6%; P = .03). There were no statistical differences in SPPB (P = .41) or frailty (P = .20). Using a proposed " @entity1 " frailty criteria, 8.7% in ADT group were frail and 56.5% were "prefrail," compared with 2.9% and 48.8% of controls (P = .02). Falls in the last year were higher in the ADT group (14.3% vs 2.8%; P = .02). In analyses controlling for age, clinical characteristics, and comorbidities, the ADT group trended toward significance for " @entity1 " frailty (P = .14) and falls (OR = 4.74, P = .11). Comorbidity significantly increased the likelihood of " @entity1 " frailty (P = .01) and falls (OR 2.02, P = .01). CONCLUSIONS: @entity0 with BCR on ADT are frailer using proposed modified " @entity1 " frailty criteria. They may have lower performance status and more falls. A larger, prospective trial is necessary to establish a causal link between ADT use and progression of frailty and disability.

title: Obese frailty, physical performance deficits, and falls in older XXXX with biochemical recurrence of @entity3 on @entity4 deprivation therapy: a case-control study.

answer: @entity0


abstract: OBJECTIVE: To perform a comparative analysis of fine needle aspiration cytology (FNAC) features of @entity0 and their significance in diagnosis. STUDY DESIGN: A retrospective evaluation of 17 @entity0 diagnosed by FNAC was done. Cytologic features were detailed and compared among different @entity0 types and with available histology. RESULTS: The 17 cases comprised @entity2 (5), @entity6 (1), @entity3 (2), @entity5 (7). @entity3 and chondromyxoid @entity1 were specifically diagnosed in all 4 cases by FNAC due to characteristic cytology. However, the cytologic appearance of @entity2 overlapped significantly with that of well-differentiated @entity5 , but the correct diagnosis was made by interpreting cytology with clinicoradiologic correlation. The cytologic features of high chondroid fragment cellularity, irregular cell arrangement in fragments, prominent nucleoli, and moderate to severe nuclear hyperchromasia and mitotic activity were limited to @entity5 . The single error consisted of a case of @entity4 , chondroblastic type, that was interpreted as @entity5 . CONCLUSION: FNAC smears interpreted in the light of clinical and radiologic findings demonstrated high diagnostic accuracy. It is important to be aware of the cytology of uncommon @entity0 such as @entity3 and chondromyxoid @entity1 as well as of the overlap of cytologic features between @entity2 and @entity5 to avoid diagnostic pitfalls.

title: Cytomorphologic features of XXXX : a comparative study.

answer: @entity0


abstract: Autoantibodies against @entity6 are strongly linked to @entity7 like @entity3 ( @entity3 ). Although anti- @entity6 antibodies have received much interest in the recent years, their biological functions remain unclear. Anti- @entity6 antibodies are strongly associated with @entity4 . Recent studies describe apoptosis as a key player in LE pathogenesis and @entity6 is an important opsonin, playing a central role in the uptake of apoptotic blebs. The aim of this study was to evaluate serum anti @entity6 antibodies, @entity6 with circulating immune complexes and correlation between serology and cutaneous apoptosis in @entity0 with @entity5 . MATERIAL AND METHODS: 79 subjects were recruited and divided into 4 groups-13 healthy controls, 26 with discoid chronic lupus (DLE), 23 with @entity3 ( @entity3 ) and 17 with @entity3 ( @entity3 ). Blood samples and skin punched-biopsy specimens were performed. Serum anti- @entity6 antibodies and @entity6 associated to the immune complexes concentrations were determined by ELISA. Cutaneous @entity1 expression was evaluated by immunohistochemistry. RESULTS: @entity3 and @entity3 @entity0 had significantly higher levels of anti- @entity6 antibodies and serum @entity6 -CIC levels when compared to healthy controls (p < 0.05). Serum anti- @entity6 antibodies correlated with @entity2 in @entity3 @entity0 (p < 0.05). Anti @entity6 antibodies levels also correlated with cutaneous @entity1 expression in @entity3 and @entity3 @entity0 (both p < 0.05). CONCLUSIONS: Anti @entity6 antibodies might play a pathogenic role in @entity3 pathogenesis and being positively associated with cutaneous apoptosis markers might be associated with a negative prognosis and secondary @entity3 development.

title: Anti XXXX antibodies in @entity5 .

answer: @entity6


abstract: Autoantibodies against @entity6 are strongly linked to @entity7 like @entity3 ( @entity3 ). Although anti- @entity6 antibodies have received much interest in the recent years, their biological functions remain unclear. Anti- @entity6 antibodies are strongly associated with @entity4 . Recent studies describe apoptosis as a key player in LE pathogenesis and @entity6 is an important opsonin, playing a central role in the uptake of apoptotic blebs. The aim of this study was to evaluate serum anti @entity6 antibodies, @entity6 with circulating immune complexes and correlation between serology and cutaneous apoptosis in @entity0 with @entity5 . MATERIAL AND METHODS: 79 subjects were recruited and divided into 4 groups-13 healthy controls, 26 with discoid chronic lupus (DLE), 23 with @entity3 ( @entity3 ) and 17 with @entity3 ( @entity3 ). Blood samples and skin punched-biopsy specimens were performed. Serum anti- @entity6 antibodies and @entity6 associated to the immune complexes concentrations were determined by ELISA. Cutaneous @entity1 expression was evaluated by immunohistochemistry. RESULTS: @entity3 and @entity3 @entity0 had significantly higher levels of anti- @entity6 antibodies and serum @entity6 -CIC levels when compared to healthy controls (p < 0.05). Serum anti- @entity6 antibodies correlated with @entity2 in @entity3 @entity0 (p < 0.05). Anti @entity6 antibodies levels also correlated with cutaneous @entity1 expression in @entity3 and @entity3 @entity0 (both p < 0.05). CONCLUSIONS: Anti @entity6 antibodies might play a pathogenic role in @entity3 pathogenesis and being positively associated with cutaneous apoptosis markers might be associated with a negative prognosis and secondary @entity3 development.

title: Anti @entity6 antibodies in XXXX .

answer: @entity5


abstract: PURPOSE: To evaluate the clinical use and accuracy of a new retinal navigating laser technology that integrates a scanning slit fundus camera system with @entity2 angiography (FA), color, red-free, and infrared imaging capabilities with a computer steerable therapeutic 532-nm laser. DESIGN: Interventional case series. @entity0 : Eighty-six eyes of 61 @entity0 with @entity1 and @entity3 treated by NAVILAS. METHODS: The imaging included digital color fundus photographs and FA. The planning included graphically marking future treatment sites (microaneurysms for single-spot focal treatment and areas of diffuse leakage for grid pattern photocoagulation) on the acquired images. The preplanned treatment was visible and overlaid on the live fundus image during the actual photocoagulation. The NAVILAS automatically advances the aiming beam location from one planned treatment site to the next after each photocoagulation spot until all sites are treated. Aiming beam stabilization compensated for @entity0 's eye movements. The pretreatment FA with the treatment plan was overlaid on top of the posttreatment color fundus images with the actual laser burns. This allowed treatment accuracy to be calculated. Independent observers evaluated the images to determine if the retinal opacification after treatment overlapped the targeted microaneurysm. MAIN OUTCOME MEASURES: Safety and accuracy of laser photocoagulation. RESULTS: The images were of very good quality compared with standard fundus cameras, allowing careful delineation of target areas on FA. Toggling from infrared, to monochromatic, to color view allowed evaluation and adjustment of burn intensity during treatment. There were no complications during or after photocoagulation treatment. An analysis of accuracy of 400 random focal targeted spots found that the NAVILAS achieved a microaneurysm hit rate of 92% when the placement of the treatment circle was centered by the operating surgeon on the microaneurysm. The accuracy for the control group analyzing 100 focal spots was significantly lower at 72% (P<0.01). CONCLUSIONS: Laser photocoagulation using the NAVILAS system is safe and achieves a higher rate of accuracy in photocoagulation treatments of @entity1 lesions than standard manual-technique laser treatment. Precise manual preplanning and positioning of the treatment sites by the surgeon is possible, allowing accurate and predictable photocoagulation of these lesions. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

title: Clinical evaluation and treatment accuracy in XXXX using navigated laser photocoagulator NAVILAS.

answer: @entity3


abstract: BACKGROUND: The pathogenesis of @entity5 -induced @entity8 (AIA) is presumed to involve the @entity5 /non-steroidal anti-inflammatory drug (NSAID)-induced abnormal metabolism of @entity9 , resulting in an increase in @entity13 (5-LO) metabolites, particularly @entity7 ( @entity7 ). However, the role of LTC(4) in the development of AIA has yet to be conclusively demonstrated. OBJECTIVE: The aim of this study was to evaluate the contribution of the lipid product LTC(4) secreted by the 5-LO pathway to the pathogenesis of AIA. METHODS: To evaluate antigen-induced @entity2 , the concentrations of T-helper type 2 cytokine in bronchoalveolar lavage fluid (BALF) obtained from @entity14 -transgenic (Tg) and @entity6 ( @entity6 ) @entity1 after challenge with ovalbumin were measured. Subsequently, the ex vivo and in vivo effects of the NSAID @entity12 were investigated in these Tg and @entity6 @entity1 by measuring the secretion of LTC(4) from @entity12 -treated BAL cells and the levels of LTC(4) in BALF following challenge with @entity12 . Finally, the @entity12 -induced airway response by the administration of pranlukast, an antagonist of the @entity11 (cs)-LT1 receptor, was analysed. RESULTS: The concentrations of @entity3 , -5, and -13 in BALF from Tg @entity1 were significantly higher than those in @entity6 @entity1 . In addition, @entity12 augmented the secretion of LTC(4) in BALF and by BAL cells in Tg @entity1 , but not in @entity6 @entity1 . Additionally, the increased airway resistance induced by @entity12 could be reduced by treatment with @entity10 . Furthermore, the secretion of LTC(4) from mast cells, eosinophils, and macrophages was increased in the allergen-stimulated @entity14 gene Tg @entity1 , even in the absence of @entity12 , as well as in BAL cells after @entity12 . CONCLUSION AND CLINICAL RELEVANCE: The over-expression of the @entity14 in a @entity1 @entity8 model also replicates the key features of AIA. And our study supports that cys-LTs play a major role in the pathogenesis of AIA in @entity0 with @entity4 .

title: Over-expression of the @entity14 gene in @entity1 reproduces @entity0 @entity5 -induced XXXX .

answer: @entity8


abstract: BACKGROUND: The pathogenesis of @entity5 -induced @entity8 (AIA) is presumed to involve the @entity5 /non-steroidal anti-inflammatory drug (NSAID)-induced abnormal metabolism of @entity9 , resulting in an increase in @entity13 (5-LO) metabolites, particularly @entity7 ( @entity7 ). However, the role of LTC(4) in the development of AIA has yet to be conclusively demonstrated. OBJECTIVE: The aim of this study was to evaluate the contribution of the lipid product LTC(4) secreted by the 5-LO pathway to the pathogenesis of AIA. METHODS: To evaluate antigen-induced @entity2 , the concentrations of T-helper type 2 cytokine in bronchoalveolar lavage fluid (BALF) obtained from @entity14 -transgenic (Tg) and @entity6 ( @entity6 ) @entity1 after challenge with ovalbumin were measured. Subsequently, the ex vivo and in vivo effects of the NSAID @entity12 were investigated in these Tg and @entity6 @entity1 by measuring the secretion of LTC(4) from @entity12 -treated BAL cells and the levels of LTC(4) in BALF following challenge with @entity12 . Finally, the @entity12 -induced airway response by the administration of pranlukast, an antagonist of the @entity11 (cs)-LT1 receptor, was analysed. RESULTS: The concentrations of @entity3 , -5, and -13 in BALF from Tg @entity1 were significantly higher than those in @entity6 @entity1 . In addition, @entity12 augmented the secretion of LTC(4) in BALF and by BAL cells in Tg @entity1 , but not in @entity6 @entity1 . Additionally, the increased airway resistance induced by @entity12 could be reduced by treatment with @entity10 . Furthermore, the secretion of LTC(4) from mast cells, eosinophils, and macrophages was increased in the allergen-stimulated @entity14 gene Tg @entity1 , even in the absence of @entity12 , as well as in BAL cells after @entity12 . CONCLUSION AND CLINICAL RELEVANCE: The over-expression of the @entity14 in a @entity1 @entity8 model also replicates the key features of AIA. And our study supports that cys-LTs play a major role in the pathogenesis of AIA in @entity0 with @entity4 .

title: Over-expression of the XXXX gene in @entity1 reproduces @entity0 @entity5 -induced @entity8 .

answer: @entity14


abstract: BACKGROUND: The pathogenesis of @entity5 -induced @entity8 (AIA) is presumed to involve the @entity5 /non-steroidal anti-inflammatory drug (NSAID)-induced abnormal metabolism of @entity9 , resulting in an increase in @entity13 (5-LO) metabolites, particularly @entity7 ( @entity7 ). However, the role of LTC(4) in the development of AIA has yet to be conclusively demonstrated. OBJECTIVE: The aim of this study was to evaluate the contribution of the lipid product LTC(4) secreted by the 5-LO pathway to the pathogenesis of AIA. METHODS: To evaluate antigen-induced @entity2 , the concentrations of T-helper type 2 cytokine in bronchoalveolar lavage fluid (BALF) obtained from @entity14 -transgenic (Tg) and @entity6 ( @entity6 ) @entity1 after challenge with ovalbumin were measured. Subsequently, the ex vivo and in vivo effects of the NSAID @entity12 were investigated in these Tg and @entity6 @entity1 by measuring the secretion of LTC(4) from @entity12 -treated BAL cells and the levels of LTC(4) in BALF following challenge with @entity12 . Finally, the @entity12 -induced airway response by the administration of pranlukast, an antagonist of the @entity11 (cs)-LT1 receptor, was analysed. RESULTS: The concentrations of @entity3 , -5, and -13 in BALF from Tg @entity1 were significantly higher than those in @entity6 @entity1 . In addition, @entity12 augmented the secretion of LTC(4) in BALF and by BAL cells in Tg @entity1 , but not in @entity6 @entity1 . Additionally, the increased airway resistance induced by @entity12 could be reduced by treatment with @entity10 . Furthermore, the secretion of LTC(4) from mast cells, eosinophils, and macrophages was increased in the allergen-stimulated @entity14 gene Tg @entity1 , even in the absence of @entity12 , as well as in BAL cells after @entity12 . CONCLUSION AND CLINICAL RELEVANCE: The over-expression of the @entity14 in a @entity1 @entity8 model also replicates the key features of AIA. And our study supports that cys-LTs play a major role in the pathogenesis of AIA in @entity0 with @entity4 .

title: Over-expression of the @entity14 gene in XXXX reproduces @entity0 @entity5 -induced @entity8 .

answer: @entity1


abstract: BACKGROUND: The pathogenesis of @entity5 -induced @entity8 (AIA) is presumed to involve the @entity5 /non-steroidal anti-inflammatory drug (NSAID)-induced abnormal metabolism of @entity9 , resulting in an increase in @entity13 (5-LO) metabolites, particularly @entity7 ( @entity7 ). However, the role of LTC(4) in the development of AIA has yet to be conclusively demonstrated. OBJECTIVE: The aim of this study was to evaluate the contribution of the lipid product LTC(4) secreted by the 5-LO pathway to the pathogenesis of AIA. METHODS: To evaluate antigen-induced @entity2 , the concentrations of T-helper type 2 cytokine in bronchoalveolar lavage fluid (BALF) obtained from @entity14 -transgenic (Tg) and @entity6 ( @entity6 ) @entity1 after challenge with ovalbumin were measured. Subsequently, the ex vivo and in vivo effects of the NSAID @entity12 were investigated in these Tg and @entity6 @entity1 by measuring the secretion of LTC(4) from @entity12 -treated BAL cells and the levels of LTC(4) in BALF following challenge with @entity12 . Finally, the @entity12 -induced airway response by the administration of pranlukast, an antagonist of the @entity11 (cs)-LT1 receptor, was analysed. RESULTS: The concentrations of @entity3 , -5, and -13 in BALF from Tg @entity1 were significantly higher than those in @entity6 @entity1 . In addition, @entity12 augmented the secretion of LTC(4) in BALF and by BAL cells in Tg @entity1 , but not in @entity6 @entity1 . Additionally, the increased airway resistance induced by @entity12 could be reduced by treatment with @entity10 . Furthermore, the secretion of LTC(4) from mast cells, eosinophils, and macrophages was increased in the allergen-stimulated @entity14 gene Tg @entity1 , even in the absence of @entity12 , as well as in BAL cells after @entity12 . CONCLUSION AND CLINICAL RELEVANCE: The over-expression of the @entity14 in a @entity1 @entity8 model also replicates the key features of AIA. And our study supports that cys-LTs play a major role in the pathogenesis of AIA in @entity0 with @entity4 .

title: Over-expression of the @entity14 gene in @entity1 reproduces @entity0 XXXX -induced @entity8 .

answer: @entity5


abstract: BACKGROUND: The pathogenesis of @entity5 -induced @entity8 (AIA) is presumed to involve the @entity5 /non-steroidal anti-inflammatory drug (NSAID)-induced abnormal metabolism of @entity9 , resulting in an increase in @entity13 (5-LO) metabolites, particularly @entity7 ( @entity7 ). However, the role of LTC(4) in the development of AIA has yet to be conclusively demonstrated. OBJECTIVE: The aim of this study was to evaluate the contribution of the lipid product LTC(4) secreted by the 5-LO pathway to the pathogenesis of AIA. METHODS: To evaluate antigen-induced @entity2 , the concentrations of T-helper type 2 cytokine in bronchoalveolar lavage fluid (BALF) obtained from @entity14 -transgenic (Tg) and @entity6 ( @entity6 ) @entity1 after challenge with ovalbumin were measured. Subsequently, the ex vivo and in vivo effects of the NSAID @entity12 were investigated in these Tg and @entity6 @entity1 by measuring the secretion of LTC(4) from @entity12 -treated BAL cells and the levels of LTC(4) in BALF following challenge with @entity12 . Finally, the @entity12 -induced airway response by the administration of pranlukast, an antagonist of the @entity11 (cs)-LT1 receptor, was analysed. RESULTS: The concentrations of @entity3 , -5, and -13 in BALF from Tg @entity1 were significantly higher than those in @entity6 @entity1 . In addition, @entity12 augmented the secretion of LTC(4) in BALF and by BAL cells in Tg @entity1 , but not in @entity6 @entity1 . Additionally, the increased airway resistance induced by @entity12 could be reduced by treatment with @entity10 . Furthermore, the secretion of LTC(4) from mast cells, eosinophils, and macrophages was increased in the allergen-stimulated @entity14 gene Tg @entity1 , even in the absence of @entity12 , as well as in BAL cells after @entity12 . CONCLUSION AND CLINICAL RELEVANCE: The over-expression of the @entity14 in a @entity1 @entity8 model also replicates the key features of AIA. And our study supports that cys-LTs play a major role in the pathogenesis of AIA in @entity0 with @entity4 .

title: Over-expression of the @entity14 gene in @entity1 reproduces XXXX @entity5 -induced @entity8 .

answer: @entity0


abstract: It is often difficult for emergency department staff to follow up the primary closure of simple @entity1 . This is important to allow closure of the feedback loop. Consecutive @entity0 who were sutured by a single operator using the same technique were asked to send a photograph of the laceration six months and 12 months afterwards. The @entity0 had Internet access and a digital camera, or a mobile phone with a camera. They were given a leaflet with the details of the email address or mobile number to send the picture to. A reminder telephone call was made to each @entity0 at six months and 12 months, and the email address or mobile number to send the picture to was given again. In each telephone call @entity0 were asked to grade the healing on a 5-point scale from 1 = very happy to 5 = very unhappy. At 13 months all @entity0 were re-contacted and reminded again. Fifty @entity0 were included in the study (33 males). The cause of injury was sport in 17 @entity0 , assault in 18 and accidents in 15. At six months, 23 @entity0 stated that they were happy and 27 were very happy with the scar. The mean score was 1.5. At 12 and 13 months, four @entity0 were happy and 46 very happy. The mean score was 1.1. Twenty-four @entity0 said they would use a computer/camera to send in the follow-up image, and 26 @entity0 had a mobile phone with a camera and said they would use that. Despite the reminders, no @entity0 sent a photograph. The results provide no evidence to support the use of photographs sent by email or text message for the follow-up of @entity1 sutured in the emergency department.

title: Electronic follow-up of XXXX in the emergency department.

answer: @entity1


abstract: BACKGROUND: @entity2 ( @entity2 ) is rare in @entity0 with @entity1 ( @entity1 ). There are limited data on the utility of catheter ablation for the treatment of @entity2 in this population. This study details a series of case reports from multiple centers where combined epicardial-endocardial ablation was performed in a highly selected group of @entity0 with @entity1 -related @entity2 . METHODS AND RESULTS: The cohort consisted of 10 @entity0 with @entity1 -related @entity2 . Pericardial access was achieved using the percutaneous subxyphoid approach. Epicardial and endocardial ventricular 3D bipolar voltage maps were generated. Ablation sites were identified using a combination of entrainment, activation, late/fractionated potential, and pace mapping. Electrophysiological-identified @entity3 was present in 8 (80%) @entity0 , @entity3 in 6 (60%), and no scar in 1 (10%). In the 5 @entity0 with inducible, stable @entity2 , 3 cases were successfully terminated with ablation from the epicardium and 1 from the endocardium. The case that failed catheter ablation required surgical cryoablation to abolish the incessant VT. In the remaining 5 @entity0 , 4 underwent epicardial and endocardial ablation of sites with good pace maps and late/fractionated potentials. No ablation was performed in the remaining @entity0 because of noninducibility and lack of identifiable scar. After 37  17 months (limits, 2 to 62 months; median, 37 months), the freedom from recurrent implantable cardioverter-defibrillator shocks was 78% (7/9 @entity0 ) in those who underwent ablation. CONCLUSIONS: In highly selected @entity0 with @entity1 , combined epicardial and endocardial mapping and ablation is a feasible and reasonably efficacious option for @entity2 if refractory to aggressive trials of antiarrhythmic drugs and antitachycardia pacing.

title: Long-term outcomes of combined epicardial and endocardial ablation of monomorphic @entity2 related to XXXX .

answer: @entity1


abstract: BACKGROUND: @entity2 ( @entity2 ) is rare in @entity0 with @entity1 ( @entity1 ). There are limited data on the utility of catheter ablation for the treatment of @entity2 in this population. This study details a series of case reports from multiple centers where combined epicardial-endocardial ablation was performed in a highly selected group of @entity0 with @entity1 -related @entity2 . METHODS AND RESULTS: The cohort consisted of 10 @entity0 with @entity1 -related @entity2 . Pericardial access was achieved using the percutaneous subxyphoid approach. Epicardial and endocardial ventricular 3D bipolar voltage maps were generated. Ablation sites were identified using a combination of entrainment, activation, late/fractionated potential, and pace mapping. Electrophysiological-identified @entity3 was present in 8 (80%) @entity0 , @entity3 in 6 (60%), and no scar in 1 (10%). In the 5 @entity0 with inducible, stable @entity2 , 3 cases were successfully terminated with ablation from the epicardium and 1 from the endocardium. The case that failed catheter ablation required surgical cryoablation to abolish the incessant VT. In the remaining 5 @entity0 , 4 underwent epicardial and endocardial ablation of sites with good pace maps and late/fractionated potentials. No ablation was performed in the remaining @entity0 because of noninducibility and lack of identifiable scar. After 37  17 months (limits, 2 to 62 months; median, 37 months), the freedom from recurrent implantable cardioverter-defibrillator shocks was 78% (7/9 @entity0 ) in those who underwent ablation. CONCLUSIONS: In highly selected @entity0 with @entity1 , combined epicardial and endocardial mapping and ablation is a feasible and reasonably efficacious option for @entity2 if refractory to aggressive trials of antiarrhythmic drugs and antitachycardia pacing.

title: Long-term outcomes of combined epicardial and endocardial ablation of monomorphic XXXX related to @entity1 .

answer: @entity2


abstract: BACKGROUND: The introduction of antipsychotic medication has been a major advance in the treatment of @entity2 and allows millions of @entity0 to live outside of institutions. It is generally believed that long-acting intramuscular antipsychotic medication is the most effective approach to increasing medication adherence and thereby reduce relapse in high-risk @entity0 with @entity2 , but the data are scant. PURPOSE: To report the design of a study to assess the effect of long-acting injectable @entity3 in unstable @entity0 and under more realistic conditions than previously studied and to evaluate the effect of this medication on @entity1 inpatient hospitalization, @entity2 symptoms, quality of life, medication adherence, side effects, and health care costs. METHODS: The trial was an open randomized clinical comparative effectiveness trial in @entity0 with @entity2 or @entity4 in which parenteral @entity3 was compared to an oral antipsychotic regimen selected by each control @entity0 's psychiatrist. @entity0 had unstable @entity1 disease defined by recent hospitalization or exhibition of unusual need for @entity1 services. The primary endpoint was hospitalization for @entity1 indications; the secondary endpoint was @entity1 symptoms. RESULTS: Overall, 382 @entity0 were randomized. Determination of a @entity0 ' competency to understand the elements of informed consent was addressed. The use of a closed-circuit TV interview for psychosocial measures provided an economical, high quality, reliable means of collecting data. A unique method for insuring that usual care was optimal was incorporated in the follow-up of all subjects. LIMITATIONS: @entity0 with @entity2 or @entity4 and with the common co-morbid illnesses seen in the VA are a challenging group of subjects to study in long-term trials. Some techniques unique in the VA and found useful may not be generalizable or applicable in other research or treatment settings. CONCLUSIONS: The trial tested a new antipsychotic medication early in its adoption in the Veterans Health Administration. The VA has a unique electronic medical record and database which can be used to identify the endpoint, that is, first hospitalization due to a @entity1 problem, with complete ascertainment. Several methodologic solutions addressed competency to understand elements of consent, the costs and reliability of collecting interview data gathering, and insuring usual care.

title: Challenges in the design and conduct of controlled clinical effectiveness trials in XXXX .

answer: @entity2


abstract: BACKGROUND: Low-dose oral contraceptives can still cause @entity9 with serious neurologic or @entity7 . @entity0 : A  22-year-old @entity0 having used oral contraceptives for several months noticed @entity5 . One tablet of her contraceptive contained @entity12 (0.03  mg) and @entity14 (2  mg). RESULT: Because of the @entity13 , the @entity0 could only read with her right eye. She presented complete left inferior @entity10 , indicating a hemicentral retinal @entity6 . Visual acuity in both eyes was 20  /  20. The left fundus revealed a distinct @entity11 in the area superior to the optic disc and macula due to vascular disturbances of the superior temporal superior and superior nasal retinal arteries. The right eye was normal. Fluorescein angiography revealed recanalized arteries in the superior retinal area with conspiciously early dye filling as a paradoxical sign. Doppler sonography of the neck and orbital arteries and transesophageal echocardiography (TEE) findings were inconspicious. However, blood examination revealed an elevated thrombin-antithrombin complex and reduced free protein S. CONCLUSION: @entity8 can be a side effect of oral contraceptives. Even nowadays, @entity0 taking contraceptives risk the danger of @entity6 especially if the @entity0 suffers from @entity3 , @entity1 , have @entity4 , or if she is a chronic smoker. Before treatment with oral contraceptives commences, a thorough medical examination is necessary. If the family history reveals prominent cardiovascular risk factors, testing for @entity2 is recommended. Even nowadays, @entity0 should be warned of the risk of @entity5 as a potential side-effect associated with oral contraceptives.

title: [Hemicentral retinal XXXX due to oral contraceptives].

answer: @entity6


abstract: OBJECTIVE: The QUASAR (Quality Assessment Score and Cardiovascular Outcomes in Italian @entity1 @entity0 ) study aimed to assess whether a quality-of-care summary score predicted the development of cardiovascular (CV) events in @entity0 with @entity2 2 @entity1 . RESEARCH DESIGN AND METHODS: In 67 @entity1 clinics, data on randomly selected @entity0 were extracted from electronic medical records. The score was calculated using process and outcome indicators based on monitoring, targets, and treatment of @entity4 , blood pressure, LDL @entity3 , and microalbuminuria. The score ranged from 0 to 40. RESULTS: Overall, 5,181 @entity0 were analyzed; 477 (9.2%) @entity0 developed a CV event after a median follow-up of 28 months. The incidence rate (per 1,000 @entity0 -years) of CV events was 62.4 in @entity0 with a score of <15, 41.0 in those with a score between 20 and 25 and 36.7 in those with a score of >25. Multilevel analysis, adjusted for clustering and case-mix, showed that the risk to develop a new CV event was 84% higher in @entity0 with a score of <15 (incidence rate ratio [IRR] = 1.84; 95% confidence interval [CI] 1.29-2.62) and 17% higher in those with a score between 15 and 25 (IRR = 1.17; 95% CI 0.93-1.49) compared with those with a score of >25. Mean quality score varied across centers from 16.5    7.5 to 29.1    6.3. When the score was tested as the dependent variable, it emerged that 18% of the variance in the score could be attributed to setting characteristics. CONCLUSIONS: Our study documented a close relationship between quality of @entity1 care and long-term outcomes. A simple score can be used to monitor quality of care and compare the performance of different centers/physicians.

title: Quality of XXXX care predicts the development of cardiovascular events: results of the AMD-QUASAR study.

answer: @entity1


abstract: OBJECTIVE: To investigate the effect of Panax Notoginseng @entity2 (PNS) on tendon healing in bone tunnel. METHODS: The experiment was performed in the animal laboratory, Wangjing hospital from April to August, 2010. All the experiment procedures were accorded with the animal ethical requirements. Twenty @entity1 were randomly divided into blank control group and PNS group with 10 animals in each group. Anterior cruciate ligament reconstruction with toe extensor tendon was done in knee joints of @entity1 by suspend fixation model. PNS was injected in bone tunnel of @entity1 in PNS group, and nothing was given to blank group. Specimens were collected at 4 and 8 weeks after surgery. Sections were stained with HE stain to observe the changes of interface tissue between bone tunnel and tendon graft. Interface types were classified according to Yamakado method. RESULTS: At 4 weeks after surgery, the interface was filled with connective tissue in both group, while at 8 weeks, there was not obvious gap between bone and tendon graft in both groups under macrography. Under microscope, there were more fibroblast in the PNS group. There was larger new bone formation area in PNS group. The classification on the Yamakado type was significantly different between two group (P < 0.05). CONCLUSION: PNS can enhance @entity0 in bone tunnel, and promote the connection between tendon and bone. The study lacks quantitative analysis of those criteria, and the mechanics of the promotion of @entity0 has not been totally clear.

title: [Effect of Panax Notoginseng XXXX on autograft tendon healing in bone tunnel: interface histological characteristics].

answer: @entity2


abstract: The clinical course of 29 liver graft recipients in the Cambridge/King's College Hospital series who have received @entity3 (CyA) for up to five years (median 40 months) was analysed with particular reference to the immunosuppressive effectiveness and adverse effects of the drug. Eight @entity0 had been maintained on @entity7 and @entity5 for two to six years before treatment was changed to @entity3 and the remainder were started on @entity3 after operation. Results in both groups over a one to five year study period are similar, and showed that @entity3 was effective in maintaining adequate immunosuppression, allowing complete withdrawal of prednisolone in 16 @entity0 . Episodes of rejection were observed in only three @entity0 and in two of these it was of the chronic 'vanishing bile duct' variety. Some evidence of nephrotoxicity (serum @entity8 greater than 150 mumol/l) occurred in 72 per cent (21 of 29 @entity0 ) but it was necessary to discontinue treatment in only two. @entity2 , occasionally of sudden onset, was found in nine @entity0 and led to the withdrawal of the drug in two. Additional @entity6 drug treatment was required in five. In one other @entity0 @entity3 was discontinued on account of severe @entity1 . @entity3 was withdrawn in two further @entity0 . Withdrawal led to considerable risk of acute rejection and increased doses of @entity4 as well as substitution of @entity5 were required at that time.

title: Long-term use of XXXX in liver grafting.

answer: @entity3